Mirum Pharmaceuticals, Inc. — Form 8-K Summary
Reporting context: Current report covering events announced September 25 and September 28, 2026. This filing reports a product approval and clinical-trial results; it does not provide quarterly or annual financial statements.
Business developments
- Atebrioz (zilurgisertib): The FDA approved the once-daily oral treatment to reduce total new heterotopic ossification volume in adults and patients aged 12 and older with fibrodysplasia ossificans progressiva (FOP). Incyte developed the drug and licensed it to Mirum for worldwide development and commercialization. U.S. commercial availability is expected in October 2026 through Mirum Access Plus.
- Brelovitug: Mirum reported that the Phase 3 portion of AZURE-1 met its primary endpoint in chronic hepatitis delta (HDV). Brelovitug remains investigational and is not described as FDA-approved.
Clinical results and other key metrics
| Program | Reported results |
|---|---|
| Atebrioz, PROGRESS Cohort 1 | At Week 24, mean total new HO lesion volume decreased by 3.2 cm3 with zilurgisertib versus an increase of 24.6 cm3 with placebo. Treatment effects were maintained through Week 48 of the open-label extension. The filing says treatment was generally well tolerated during the 24-week controlled period; no adverse events led to discontinuation or dose reduction. |
| Brelovitug, AZURE-1 Phase 3, Week 24 | The combined endpoint of virologic response and ALT normalization was achieved by 56% on 300 mg weekly, 45% on 900 mg every four weeks, and 0% in the delayed-treatment arm (p<0.0001 for each comparison). Virologic response was 86%, 85%, and 0%, respectively; ALT normalization was 63%, 54%, and 0%. |
| Brelovitug, AZURE-1 Phase 2b, Week 48 | The combined endpoint was achieved by 55% in each dose group. The filing reports HDV RNA below the lower limit of quantification in 80% on 300 mg weekly and 40% on 900 mg every four weeks. No new safety signals were reported through Week 48. |
Financial information and material changes
- The filing provides no revenue, profit, cash flow, margin, debt, or liquidity figures, and no direct comparison of the company’s financial performance with a prior period.
- Management estimates annual revenue potential of more than $1 billion for brelovitug in HDV and greater than $200 million for Atebrioz in its approved FOP population. These are potential-market estimates, not reported revenue or guidance on realized sales.
Outlook, commentary, and risks
- Topline AZURE-4 results, the second pivotal study intended to support a U.S. registration package for brelovitug, are expected in Q4 2026. Mirum expects to submit a BLA in the first half of 2027 and anticipates a potential U.S. launch in Q4 2027. Topline AZURE-2 and AZURE-3 results are expected in the second half of 2027.
- Zilurgisertib’s marketing authorization application is under review by the European Medicines Agency. Enrollment is complete in PROGRESS Cohort 2, and enrollment is underway in Cohort 3.
- The company cautions that forward-looking statements—including commercial timing, patient costs, trial results, regulatory submissions, and launch expectations—are subject to risks and may not be achieved. It identifies drug-development and business risks and refers investors to its other SEC filings.
Important facts for investors to verify
- U.S. Atebrioz launch timing, access arrangements, and the basis and scope of the stated revenue-potential estimate.
- Full AZURE-1 Phase 3 results, including complete safety data, when presented at a medical congress, and the AZURE-4 topline results expected in Q4 2026.
- Whether brelovitug’s remaining clinical and regulatory milestones support the anticipated BLA timing and potential launch.
- The EMA review status and further PROGRESS study developments for zilurgisertib.
- Financial performance and liquidity: this 8-K does not provide the figures needed to assess them.